To the best of our knowledge, this is the first study that evaluates the clinical relevance of RLR in patients with PBC. The results showed that RLR, an easily-acquired parameter through blood routine tests, can effectively differentiate advanced cirrhosis from early cirrhosis. RLR may also serve as a valuable marker for estimating the therapeutic response and to predict prognosis.
PBC is a chronic disease that is increasingly being recognized in recent years and its prevalence is growing worldwide. The disease onset is typically insidious and is associated with non-specific symptoms. Pruritus and fatigue were reported in 80% and 20% to 70% patients, respectively. Symptoms of decompensated cirrhosis may be seen in advanced stage. The presence of AMA is an important diagnostic marker of PBC that has a sensitivity and specificity of 90% to 95%.
Liver biopsy is still the gold standard for diagnosis and staging of PBC and is useful for monitoring of therapeutic response. Moreover, it can also predict prognosis of PBC. Liver biopsy is essential when PBC-specific antibodies are absent, or when coexisting autoimmune hepatitis (AIH) or non-alcoholic steatohepatitis is suspected. However, it is not essential and, indeed, not accepted by many patients owing to its invasive nature and the associated risk of complications.[25,26] The risk associated with liver biopsy in patients with advanced stage of cirrhosis is much higher than that in patients with early stage. Patients with early-stage disease generally show good clinical and biochemical response to ursodeoxycholic acid (UDCA) therapy. Patients with advanced-stage cirrhosis tend to easily develop hepatic decompensation and show poor response to UDCA. In addition, UDCA treatment in advanced stage does not decrease the risk of mortality or hepatocellular carcinoma in patients with PBC. The prognosis of patients with early stage of cirrhosis is better than that of patients with advanced stage. Thus, figuring out the stage of PBC with noninvasive method is a key imperative.
Parameters like RDW, RPR, AST/ALT ratio (AAR), and neutrophil to lymphocyte ratio (NLR) were shown to predict the degree of cirrhosis. In a study by Lou et al, RDW value was shown to directly correlate with the severity of cirrhosis. In addition, RDW was shown to predict 3-month mortality in patients with hepatitis B. In a study by Chen et al, RPR was shown to accurately predict the degree of cirrhosis. Use of this index may reduce the need for liver biopsy. Similar results pertaining to the ability of RPR to predict the degree of cirrhosis were reported by Taefi et al. Another study from Sweden concluded that the AST/ALT ratio may help identify cirrhosis in patients with PBC. Alkhouri et al showed a positive correlation between NLR and the severity of cirrhosis.
RDW reflects the variation in the distribution of RBC volume in circulation. High values imply greater variation that may relate to anemia. Also, RDW is a marker of chronic inflammation. RDW has been shown to be related with various diseases, such as cardiovascular diseases, renal diseases, and some malignant diseases.[13,15,40] In this study, RDW increased with increase in the severity of disease. Thrombocytopenia is a well-known complication of cirrhosis; therefore, platelet count decreases with the severity of cirrhosis. PBC is an autoimmune disease. Lymphocytes play a crucial role in immune surveillance. A decrease in lymphocyte count may relate with apoptosis and dysfunction of immune cells. Development of advanced cirrhosis is associated with a progressive decrease in lymphocyte count.
In this study, we observed significant difference between patients with early and advanced cirrhosis with respect to RPR, RLR, APRI, and FIB-4. In addition to APRI and FIB-4, which are commonly used noninvasive markers of disease severity, we observed a particularly good ability of RPR and RLR to distinguish between early and advanced cirrhosis. The diagnostic specificity of both RPR (86.4%) and RLR (78.3%) was higher than that of APRI and FIB-4. However, the sensitivity was lower than that of APRI and FIB-4. Therefore, RLR may serve as a valuable supplement to APRI and FIB-4 owing to its high specificity. RLR showed the highest AUROC among all the noninvasive markers (0.744). The results pertaining to APRI in this study contradict those reported from a study conducted in Turkey, in which APRI value decreased with increase in the severity of PBC. Of note, there were no significant differences pertaining to baseline data between patients with early-stage and late-stage disease in the Turkish study; this may have contributed to the contradictory results. Nonetheless, our findings pertaining to APRI and FIB-4 are consistent with those of other studies.[42,43]
There were some limitations of this study. First, the sample size of this study was limited. Most patients in our hospital tend to refuse biopsy owing to the invasive nature and pain associated with this procedure. In addition, patients with decompensated cirrhosis are not suitable for invasive procedure due to the high risk of hemorrhage. In our further study, more patients will be enrolled to minimize the bias caused by sample size. Second, this was a single-center retrospective study, which lacked data from other areas. The results need to be validated internally and externally. We will enroll patients from other areas prospectively to validate these results.
. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386:1565–75.
. Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis 2014;34:329–33.
. Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev 2014;13:445–50.
. Taghavi SA, Majd SK, Sianati M, et al. Prevalence of IgG-4-associated cholangiopathy based on serum IgG-4 levels in patients with primary sclerosing cholangitis and its relationship with inflammatory bowel disease. Turk J Gastroenterol 2016;27:547–52.
. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50:291–308.
. Locke GR, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52–6.
. Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, et al. Is liver biopsy still needed in children with chronic viral hepatitis. World J Gastroenterol 2015;21:12141–9.
. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive
index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
. Vallet-Pichard A, Mallet V, Pol S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology 2006;44:769author reply 769-770.
. Imanieh MH, Hakimzadeh M, Dehghani SM, et al. Aspartate aminotransferase to platelet ratio index and severity of hepatic fibrosis in children. Comp Clin Path 2015;24:1611–5.
. Trivedi PJ, Bruns T, Cheung A, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014;60:1249–58.
. Adamsson ES, Borné Y, Melander O, et al. Red blood cell distribution width is associated with incidence of atrial fibrillation. J Intern Med 2014;275:84–92.
. Yonemoto S, Hamano T, Fujii N, et al. Red cell distribution width and renal outcome in patients with non-dialysis-dependent chronic kidney disease. PLoS One 2018;13:e0198825.
. Wei J, Yang RX, Ye Q, et al. Higher risk of myocardial injury in chest pain patients with elevated red blood cell distribution width. Clin Chim Acta 2018;481:121–5.
. Cheng S, Han F, Wang Y, et al. The red distribution width and the platelet distribution width as prognostic predictors in gastric cancer. BMC Gastroenterol 2017;17:163.
. Cengiz M, Candir BA, Yilmaz G, et al. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage. World J Gastroenterol 2013;19:7412–8.
. Xu WS, Qiu XM, Ou QS, et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive
serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine (Baltimore) 2015;94:e612.
. Yilmaz B, Aydin H, Can G, et al. The relationship between fibrosis level and blood neutrophil to lymphocyte ratio in inactive hepatitis B carriers. Eur J Gastroenterol Hepatol 2014;26:1325–8.
. Liu X, He L, Han J, et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer. PLoS One 2017;12:e0170605.
. Tanaka A, Ma X, Yokosuka O, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int 2016;10:909–15.
. Leuschner U. Primary biliary cirrhosis--presentation and diagnosis. Clin Liver Dis 2003;7:741–58.
. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010;52:745–58.
. Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol 2014;13:316–26.
. European Association for the Study of the Liver. Electronic address: firstname.lastname@example.org; European Association for the Study of the LiverEASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
. J Hepatol 2017;67:145–72.
. Mueller M, Kratzer W, Oeztuerk S, et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol 2012;12:173.
. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:877–83.
. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005–13.
. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology
progression. Hepatology 1999;29:1007–12.
. Alizadeh A, Mansour-Ghanaei F, Roozdar A, et al. Laboratory tests, liver vessels color doppler sonography, and FibroScan findings in patients with nonalcoholic fatty liver disease: an observation study. J Clin Imaging Sci 2018;8:12.
. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
. Zhao Z, Liu J, Wang J, et al. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection. Int Immunopharmacol 2017;51:1–8.
. Sebastiani G, Alberti A. How far is noninvasive
assessment of liver fibrosis from replacing liver biopsy in hepatitis C. J Viral Hepat 2012;19(suppl):18–32.
. Tsai E, Lee TP. Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive
biomarkers and transient elastography. Clin Liver Dis 2018;22:73–92.
. Lou Y, Wang M, Mao W. Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B. PLoS One 2012;7:e37644.
. Chen B, Ye B, Zhang J, et al. RDW to platelet ratio: a novel noninvasive
index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 2013;8:e68780.
. Taefi A, Huang CC, Kolli K, et al. Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients. Hepatol Int 2015;9:454–60.
. Nyblom H, Björnsson E, Simrén M, et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006;26:840–5.
. Alkhouri N, Morris-Stiff G, Campbell C, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2012;32:297–302.
. He Y, Liu C, Zeng Z, et al. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. Clin Rheumatol 2018;37:161–7.
. Poludasu S, Marmur JD, Weedon J, et al. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. Thromb Haemost 2009;102:581–7.
. Tahtaci M, Yurekli OT, Bolat AD, et al. Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2015;27:1382–5.
. Wang H, Xu H, Wang X, et al. Red blood cell distribution width to platelet ratio is related to histologic severity of primary biliary cirrhosis. Medicine (Baltimore) 2016;95:e3114.
. Joshita S, Umemura T, Ota M, et al. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. J Hepatol 2014;61:1443–5.